Abstract | CONTEXT: METHODS: Between 2010 and 2016, 103 patients undergoing mastectomy after NACT and NART were recruited. After CT and RT were administrated, a completion mastectomy with IBR by latissimus dorsi flap was achieved 6 to 8 weeks later. pCR was defined by the absence of residual invasive disease in both nodes and breast. Histologic response was analyzed for each immunohistochemical subset. RESULTS: pCR was obtained for 53.4% of the patients. This pCR rate was higher in hormonal receptor negative (HER2 and triple negative) patients when compared to luminal tumours (69.7% vs 45.7%, p=0.023). DISCUSSION: The pCR rate found in this study is higher than those published in studies analyzing NACT (12.5%-27.1%). This can be explained by the combination of anthracycline and taxane, the use of trastuzumab when HER2 was overexpressed but also by RT associated to NACT. CONCLUSION: Inverting the sequence protocol for BC, requiring both CT and RT, allows more IBR without diminishing pCR and should therefore be considered as an acceptable therapeutic option.
|
Authors | J Barrou, M Bannier, M Cohen, E Lambaudie, A Gonçalves, P Bertrand, M Buttarelli, P Opinel, N Sterkers, A Tallet, C Zinzindohoué, G Houvenaeghel |
Journal | Breast (Edinburgh, Scotland)
(Breast)
Vol. 32
Pg. 37-43
(Apr 2017)
ISSN: 1532-3080 [Electronic] Netherlands |
PMID | 28033508
(Publication Type: Journal Article)
|
Copyright | Copyright © 2016 Elsevier Ltd. All rights reserved. |
Chemical References |
- Anthracyclines
- Bridged-Ring Compounds
- Taxoids
- taxane
- ERBB2 protein, human
- Receptor, ErbB-2
|
Topics |
- Adult
- Aged
- Anthracyclines
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Carcinoma In Situ
(chemistry, pathology, therapy)
- Breast Neoplasms
(chemistry, pathology, therapy)
- Bridged-Ring Compounds
(therapeutic use)
- Chemotherapy, Adjuvant
- Disease-Free Survival
- Female
- Humans
- Immunohistochemistry
- Mammaplasty
(methods)
- Mastectomy, Segmental
(methods)
- Middle Aged
- Neoadjuvant Therapy
(methods)
- Organ Sparing Treatments
(methods)
- Radiotherapy, Adjuvant
- Receptor, ErbB-2
(analysis)
- Surgical Flaps
- Taxoids
(therapeutic use)
- Time Factors
- Treatment Outcome
|